Oncology Articles

Midostaurin Shows Promise in Advanced Mastocytosis Trial
The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.
NEJM Data Highlights Daratumumab Benefit in Refractory Multiple Myeloma
Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.
Study Confirms MammaPrint's Accuracy in Assessing Treatment for Early Breast Cancer
Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.
Early Potential Seen With Immunotherapy in Glioblastoma, But Questions Remain
David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.
Levine Lends Advice on Treating Patients With mCRPC
Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.
Researcher Explores Biologic Basis for Disparities in Prostate Cancer Outcomes
Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.
Wolchok Discusses T-VEC, Other Immunotherapy Developments in Melanoma
Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.
Accurate Risk Status Assessment Critical to Prostate Cancer Care
Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.
Expert Discusses Novel Therapies, Biomarkers in mCRPC
Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.
Immunotherapy Advances Offer New Hope in Bladder Cancer
Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.